...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: RBC unregistered to registered account

narmac - IMO your wish will come true but not before a royalty has started to be paid. With the info being presented this weekend on mCRPC and the start of the TNBC trial IMO Zenith Epigenetics or ZEN-3694 will not be with us to much longer. As Bear said the safety profile is darn good. 3694 will have years of testing to go before providing royalties however, apabetalone could surprise even the most progressive of thinkers as to when it will start paying royalties into ZCC if it passes the BETon MACE trial.

All IMO, dyodd

tada

Share
New Message
Please login to post a reply